Philadelphia drug developer targets opioid alternatives with new cash in hand

Months after closing a new $3.5 million financing round, Philadelphia-based Mebias Discovery said it will deploy the funds to expand its pipeline of new drug candidates targeting gastrointestinal and inflammatory disorders. The Philadelphia Business Journal first reported on the financing in July. Medias confirmed Monday the financing was led by Viva Biotech of China and Sprout BioVentures of Boston. The company was founded in 2016 by researchers from Janssen Pharmaceuticals and Merck. It has since…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news